Complementary and Alternative Medicine Among Advanced Cancer Patients Enrolled on Phase I Trials: A Study of Prognosis, Quality of Life, and Preferences for Decision Making
Authors:
- 10 February 2007
- journal article
- supportive care-and-quality-of-life
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (5) , 548-554
Abstract
Purpose: We sought to describe complementary and alternative medicine (CAM) usage among phase I trial participants and to describe these patients' treatment decision-making preferences, awareness of prognosis, survival, and quality of life.Patients and Methods: Advanced cancer patients enrolling onto phase I trials were surveyed regarding biologically based CAM use. Decision-making preferences and awareness of prognosis were assessed using validated and/or standardized instruments. The Functional Assessment of Cancer Therapy–General instrument was used to assess quality of life. Univariate and multivariate analyses were performed to detect differences between CAM users and nonusers.Results: Of 212 interviewed patients, 34% (n = 72) described taking biologically based CAM. Median age of those taking biologically based CAM was 55 years, compared with 62 years for nonusers (P < .005). There were no statistically significant differences found between CAM usage and preferences for degree of patient involvement in medical decision making. Those patients who acknowledged that their deaths were likely to occur within 1 year were more likely to admit to prior CAM use (70% v 34%; P = .02). CAM users had poorer overall quality of life compared with nonusers (87.0 ± 12.4 v 91.2 ± 14.7; P = .007). No differences in survival were identified.Conclusion: Prior CAM use among phase I cancer trial patients studied was common and associated with age, stated acknowledgment of prognosis, and quality of life. Patients enrolling onto early-phase trials should be questioned about CAM use. Additional study is needed to determine the frequency of use of those biologically based CAM agents that threaten the accuracy of early-phase cancer trial data.Keywords
This publication has 67 references indexed in Scilit:
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002New England Journal of Medicine, 2005
- Prevalence of complementary and alternative medicine use in cancer patients during treatmentSupportive Care in Cancer, 2005
- Potential of chemotherapy?herb interactions in adult cancer patientsSupportive Care in Cancer, 2004
- Complementary and alternative medicine (CAM) use among elderly Australian women who have cancerSupportive Care in Cancer, 2003
- Milk Thistle: Is There a Role for Its Use as an Adjunct Therapy in Patients with Cancer?The Journal of Alternative and Complementary Medicine, 2003
- Cancer diagnosis and prognosis in Taiwan: Patient preferences versus experiencesPsycho-Oncology, 2003
- Does use of alternative medicine predict survival from cancer?European Journal of Cancer, 2003
- Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer AgentsJNCI: Journal of the National Cancer Institute, 1993
- Patients with terminal cancer who use alternative therapies: their beliefs and practicesSociology of Health & Illness, 1993
- Survival and Quality of Life among Patients Receiving Unproven as Compared with Conventional Cancer TherapyNew England Journal of Medicine, 1991